Montravers F, McNamara D, Landman-Parker J, Grahek D, Kerrou K, Younsi N, Wioland M, Leverger G, Talbot J N
Department of Nuclear Medicine and PET Centre, Hôpital Tenon, 4 rue de la Chine, 75020 Paris, France.
Eur J Nucl Med Mol Imaging. 2002 Sep;29(9):1155-65. doi: 10.1007/s00259-002-0861-y. Epub 2002 Jun 25.
Positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (FDG) is a very useful technique for the imaging of lymphomas in the adult population. It provides unique information about the behaviour of malignant cells and contributes to more accurate staging of the illness and better assessment of response to therapy. The purpose of this study was to evaluate the usefulness of FDG PET in childhood lymphoma compared with conventional imaging methods (CIMs) and clinical data. Between July 1998 and August 2001, 42 FDG PET examinations were performed using a dedicated PET system (27 examinations) or a hybrid coincidence PET system (15 examinations) for initial tumour staging ( n=7), restaging ( n=5) or assessment of response to therapy or residual masses ( n=30) in 27 children with Hodgkin's disease (HD) ( n=20) or non-Hodgkin's lymphoma (NHL) ( n=7). FDG PET results were compared with CIM findings and clinical data. Since 2000, a standardised questionnaire for evaluation of the clinical impact of FDG PET on both staging and therapy has been sent to the 16 referring physicians and 13 have replied. In all children, FDG PET was performed without any side-effects. FDG PET was found to be very sensitive (Se=12/12) for staging and restaging of the illness, showing more lesions than CIMs, with a 50% patient upstaging rate (6/12). It was very accurate for monitoring response to therapy and for characterisation of residual masses. False-positive results were observed in two NHL patients with thymic uptake and one false-negative result was obtained in a patient whose NHL relapsed 1 month after a negative FDG PET. The questionnaire emphasised the impact of FDG PET on clinical management, which was modified on the basis of the FDG PET results in 23% of patients. As previously demonstrated in the adult population, FDG PET appeared to be a very sensitive imaging technique for staging and restaging of lymphoma in children and was very useful for monitoring the response to therapy.
使用氟 - 18氟脱氧葡萄糖（FDG）的正电子发射断层扫描（PET）是一种对成年人群淋巴瘤成像非常有用的技术。它提供了有关恶性细胞行为的独特信息，有助于更准确地对疾病进行分期，并更好地评估对治疗的反应。本研究的目的是评估FDG PET在儿童淋巴瘤中的实用性，并与传统成像方法（CIM）和临床数据进行比较。1998年7月至2001年8月期间，使用专用PET系统（27例检查）或混合型符合PET系统（15例检查）对27例患有霍奇金病（HD）（20例）或非霍奇金淋巴瘤（NHL）（7例）的儿童进行了42次FDG PET检查，用于初始肿瘤分期（n = 7）、再分期（n = 5）或评估对治疗的反应或残留肿块（n = 30）。将FDG PET结果与CIM结果和临床数据进行比较。自2000年以来，已向16位转诊医生发送了一份关于评估FDG PET对分期和治疗的临床影响的标准化问卷，其中13位医生进行了回复。在所有儿童中，进行FDG PET检查均未出现任何副作用。发现FDG PET对疾病的分期和再分期非常敏感（Se = 12/12），显示出比CIM更多的病变，患者分期上调率为50%（6/12）。它在监测对治疗的反应和对残留肿块的特征描述方面非常准确。在两名胸腺摄取的NHL患者中观察到假阳性结果，在一名FDG PET检查结果为阴性但1个月后NHL复发的患者中获得了一个假阴性结果。问卷强调了FDG PET对临床管理的影响，23%的患者根据FDG PET结果修改了临床管理。如先前在成年人群中所证明的那样，FDG PET似乎是一种对儿童淋巴瘤分期和再分期非常敏感的成像技术，并且对监测对治疗的反应非常有用。
